 |
|
|
REFERENCES
151.
Ludwig J, Kim CH, Wiesner RH, Krom RA: Floxuridine-induced
sclerosing cholangitis: An ischemic cholangiopathy? Hepatology 9:215–218,
1989.
152.
Scharer L, Smith JD: Serum transaminase elevations
and other hepatic abnormalities in patents receiving isoniazid. Ann Intern Med 71:1113–1116,
1969.
153.
Vitug AC, Goldman JM: Hepatotoxicity from antithyroid
drugs. Horm Res 21:229–234, 1985.
154.
Leonard PA, Clegg DO, Carson CC, et al: Low dose
pulse methotrexate in rheumatoid arthritis: An 8 year experience with hepatotoxicity.
Clin Rheumatol 6:575–582, 1987.
155.
Neuberger J, Kenna JG, Nouri AK, Williams R:
Antibody-mediated hepatocyte injury in methyldopa-induced hepatotoxicity. Gut 26:1233–1239,
1985.
156.
Patterson DJ, Dew EW, Gyorkey F, et al: Niacin
hepatitis. South Med J 76:240–241, 1983.
157.
Manoukian AV, Carson JL: Nonsteroidal anti-inflammatory
drug-induced hepatic disorders: Incidence and prevalence. Drug Safe 15:64–71,
1996.
158.
Zimmerman HJ, Lewis JH: Drug-induced cholestasis.
Med Toxicol 2:112–160, 1987.
159.
Zimmerman HJ: Hepatotoxicity. Dis Mon 39:675–669,
1993.
160.
Adcock KG, MacElroy DE, Wolford ET, et al: Pemoline
therapy resulting in liver transplantation. Ann Pharmacother 32:422–425, 1998.
161.
MMWR Morb Mortal Wkly Rep 50:733, 2001.
162.
Wokke J: Riluzole. Lancet 348:795–799,
1996.
163.
Haupt NA, Rovere GD: Anabolic steroids: A review
of the literature. Am J Sports Med 12:469–475, 1984.
164.
Lindgren A, Olsson R: Liver damage associated
with low dose oral contraceptives. J Intern Med 234:287–292, 1993.
165.
Monteith DK, Emmerling MR, Garvin J, Theiss JC:
Cytotoxicity study of tacrine, structurally and pharmacologically related compounds
using rat hepatocytes. Drug Chem Toxicol 19:71–75, 1996.
166.
Hunt CM, Washington K: Tetracycline-induced bile
duct paucity and prolonged cholestasis. Gastroenterology 107:1844–1847, 1994.
167.
Olanow CW: Tolcapone and hepatotoxic effects.
Tasmar Advisory Panel. Arch Neurol 57:263–267, 2000.
168.
Bashir RM, Lipman TO: Hepatobiliary toxicity
of total parenteral nutrition in adults. Gastroenterol Clin North Am 24:1003–1025,
1995.
169.
Rimmer EM, Richens A: An update on sodium valproate.
Pharmacotherapy 5:171–185, 1985.
170.
Geubal AA, DeGalocsy C, Rahirer J, Dive C: Liver
damage caused by therapeutic vitamin A administration: Estimation of dose-related
toxicity in 41 cases. Gastroenterology 100:1701–1709, 1991.
171.
Reinus JF, Persky S, Burkiewicz JS, et al: Severe
liver injury after treatment with the leukotriene antagonist zafirlukast. Ann Intern
Med 133:964–968, 2000.
172.
Whiting PW, Clouston A, Kerlin P: Black cohosh
and other herbal remedies associated with acute hepatitis. Med J Aust 177:440–443,
2002.
173.
Benninger J, Schneider HT, Schuppan D, et al:
Acute hepatitis induced by greater celandine (Chelidonium majus).
Gastroenterology 117:1234–1237, 1999.
174.
Gordon DW, Rosenthal G, Hart J, et al: Chaparral
ingestion: The broadening spectrum of liver injuries caused by herbal medications.
JAMA 273:489–490, 1995.
175.
Winship KA: Toxicity of comfrey. Adverse Drug
React Toxicol Rev 10:47–59, 1991.
176.
Miller LG: Herbal medicinals: Selected clinical
considerations focusing on known or potential drug-herb interactions. Arch Intern
Med 158:2200–2211, 1998.
177.
Lekhelal M, Pessayre D, Lereau JM, et al: Hepatotoxicity
of the herbal medicine germander. Metabolic activation of its furano diterpenoids
by cytochrome P450 3A depletes cytoskeleton-associated protein thiols and forms plasma
membrane blebs in hepatocytes. Hepatology 24:212–221, 1996.
178.
Horowitz RS, Feldhaus K, Dart RC, et al: The
clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med 156:899–903, 1996.
179.
Wooltorton E: Herbal kava: Reports of liver
toxicity. CMAJ 166:777–780, 2002.
180.
Stedman C: Herbal hepatotoxicity. Semin Liver
Dis 22:195–206, 2002.
181.
Haouzi D, Lekehal M, Moreau M, et al: Cytochrome
P450-generated reactive metabolites cause mitochondrial permeability transition,
caspase activation, and apoptosis in rat hepatocytes. Hepatology 32:303–311,
2000.
182.
Moseley RH: Sepsis-associated cholestasis. Gastroenterology
112:302–306, 1997.
183.
Grieg JD, Krukowski ZH, Matheson NA: Surgical
morbidity and mortality in one hundred twenty nine patients with obstructive jaundice.
Br J Surg 75:216–219, 1988.
184.
Gonullu NN, Canturk NZ, Utkan NZ, et al: Factors
affecting surgical morbidity and mortality in patients with obstructive jaundice.
Materia Medica Polona 30:6–11, 1998.
185.
Dixon JM, Armstrong CP, Duff SW, Davies GC: Factors
affecting morbidity and mortality after surgery for obstructive jaundice: A review
of 373 patients. Gut 24:845–852, 1983.
186.
Wait RB, Kahng KU: Renal failure complicating
obstructive jaundice. Am J Surg 157:256–263, 1989.
187.
Green J, Better OS: Systemic hypotension and
renal failure in obstructive jaundice—mechanistic and therapeutic aspects.
J Am Soc Nephrol 5:1853–1871, 1995.
188.
Kramer HJ, Schwarting K, Backer A, Meyer-Lehnert
H: Renal endothelin system in obstructive jaundice: Its role in impaired renal
function of bile-duct ligated rats. Clin Sci 92:579–585, 1997.
189.
Kramer HJ: Impaired renal function in obstructive
jaundice: Roles of the thromboxane and endothelin systems. Nephron 77:1–12,
1997.
190.
Inan M, Sayek I, Tel BC, Sahin-Erdemli I: Role
of endotoxin and nitric oxide in the pathogenesis of renal failure in obstructive
jaundice. Br J Surg 84:943–947, 1997.
191.
Wahbah AM, el-Hefny MO, Wafa EM, et al: Perioperative
renal protection in patients with obstructive jaundice using drug combinations.
Hepatogastroenterology 47:1691–1698, 2000.
192.
Sanyal AJ, Stravitz RT: Acute liver failure.
In Zakim D, Boyer D (eds): Hepatology: A Textbook
of Liver Disease. Philadelphia, WB Saunders, 2003, pp 445–496.
193.
McCammon RL, Stoelting RK, Madura JA: Effects
of butorphanol, nalbuphine, and fentanyl on intrabiliary tract dynamics. Anesth
Analg 63:139–142, 1984.
194.
Radnay PA, Duncalf D, Novakovic M, Lesser ML:
Common bile duct pressure changes after fentanyl, morphine, meperidine, butorphanol,
and naloxone. Anesth Analg 63:441–444, 1984.
195.
Jones RM, Detmer M, Hill AB, et al: Incidence
of choledochoduodenal sphincter spasm during fentanyl-supplemented anesthesia. Anesth
Analg 60:638–640, 1981.
196.
Greaves R, Miller J, O'Donnell L, et al: Effect
of the nitric oxide donor, glyceryl trinitrate, on human gall bladder motility.
Gut 42:410–413, 1998.
197.
Madacsy L, Velosy B, Szepes A, et al: Effect
of nitric oxide on gallbladder motility in patients with acalculous biliary pain:
A cholescintigraphic study. Dig Dis Sci 47:1975–1981, 2002.
198.
Fragen RJ, Fatima V, Spies S, Erwin WD: The effect
of remifentanil on biliary tract drainage into the duodenum. Anesth Analg 89:1561,
1999.
199.
Riordan SM, Williams R: Treatment of hepatic
encephalopathy. N Engl J Med 337:473–479, 1997.
200.
Blei A, Larsen FS: Pathophysiology of cerebral
edema in fulminant hepatic failure. J Hepatol 31:771–776, 1999.
201.
Ochs A, Rossle M, Haag K, et al: The transjugular
intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl
J Med 332:1192–1197, 1995.
202.
Pomier-Layrargues G, Giguere JF, Lavoie J, et
al: Flumazenil in cirrhotic patients in hepatic coma: A randomized double-blind
placebo-controlled crossover trial. Hepatology 19:32–37, 1994.
203.
Clemmesen JO, Gerbes AL, Gulberg V, et al: Hepatic
blood flow and splanchnic oxygen consumption in patients with liver failure. Effect
of high-volume plasmapheresis. Hepatology 29:347–355, 1999.
204.
Menon KVN, Kamath PS: Managing the complications
of cirrhosis. Mayo Clin Proc 75:501–509, 2000.
205.
Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland
LJ: Octreotide. N Engl J Med 334:246–254, 1996.
206.
Roberts LR, Kamath PS: Ascites and hepatorenal
syndrome: Pathophysiology and management. Mayo Clin Proc 71:874–881, 1996.
207.
Epstein M: Hepatorenal syndrome: Emerging perspectives
of pathophysiology and therapy. J Am Soc Nephrol 4:1735–1753, 1994.
208.
Lange PA, Stoller JK: The hepatopulmonary syndrome.
Ann Intern Med 122:521–529, 1995.
209.
Quiroga J, Sangro B, Nunez M: Transjugular intrahepatic
portosystemic shunt in the treatment of refractory ascites: Effect on clinical,
renal, humoral and hemodynamic parameters. Hepatology 21:986–984, 1995.
210.
Fong Y, Cohen J, Fortner J: Liver resection for
colorectal metastases. J Clin Oncol 15:938–946, 1997.
211.
Littlewood K: Anesthetic considerations for hepatic
cryotherapy. Semin Surg Oncol 14:116–121, 1998.
